<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274794</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-3600</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-3600</secondary_id>
    <secondary_id>CASE-CCF-0467</secondary_id>
    <nct_id>NCT00274794</nct_id>
  </id_info>
  <brief_title>VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL</brief_title>
  <official_title>A Prospective Randomized Trial of VP-16 Plus G-CSF Plus Rituximab vs VP-16 Plus G-CSF Alone for Peripheral Blood Progenitor Cell Mobilization Prior to Autologous Stem Cell Transplantation for B Cell Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide,
      work in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing. Giving colony-stimulating factors, such as G-CSF, monoclonal
      antibodies, such as rituximab, or chemotherapy, such as etoposide, helps stem cells move from
      the bone marrow to the blood so they can be collected and stored until transplant. Giving
      etoposide and G-CSF together with rituximab before a peripheral stem cell transplant may be
      an effective treatment for non-Hodgkin's lymphoma.

      PURPOSE: This randomized clinical trial is studying how well giving etoposide and G-CSF with
      or without rituximab works in treating patients who are undergoing an autologous peripheral
      stem cell transplant for B-cell non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine whether mobilization with etoposide and filgrastim (G-CSF) with or without
           rituximab influences CD34+ cell yield in patients undergoing autologous peripheral blood
           stem cell transplantation for B-cell non-Hodgkin's lymphoma.

        -  Determine the acute toxicity of rituximab in combination with etoposide and G-CSF for
           peripheral blood stem cell mobilization in these patients.

      OUTLINE: This is a randomized study.

        -  Stem cell mobilization: Patients are randomized to 1 of 2 mobilization arms.

             -  Arm I: Patients receive rituximab IV over 4 hours on days 1, 8, and 15. Patients
                also receive etoposide IV over 4 hours on day 15 and filgrastim (G-CSF)
                subcutaneously (SC) beginning on day 17 and continuing until approximately day 25.
                Patients then undergo apheresis over 5 days or until an adequate amount of stem
                cells are collected. After stem cell collection is completed, patients proceed to
                the preparative regimen.

             -  Arm II: Patients receive etoposide IV over 4 hours on day 1 and G-CSF SC beginning
                on day 3 and continuing until approximately day 11. Patients then undergo apheresis
                over 5 days or until an adequate amount of stem cells are collected. After stem
                cell collection is completed, patients proceed to the preparative regimen.

        -  Preparative regimen: Patients receive oral busulfan once daily on days -8 to -4,
           etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 2 hours on days -3 and
           -2.

        -  Autologous peripheral blood stem cell transplantation (PBSCT): Patients undergo
           autologous PBSCT on day 0. Beginning on day 5, patients receive G-CSF SC or IV once
           daily until blood counts recover.

      After completion study treatment, patients are followed periodically for 10 years.

      PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate CD34+ cell yields with the addition of rituximab</measure>
    <time_frame>At least two weeks prior to transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute toxicity of rituximab, etoposide, and filgrastim (G-CSF)</measure>
    <time_frame>100 days post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituxan + Etoposide + G-CSF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide + G-CSF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide</description>
    <arm_group_label>Rituxan + Etoposide + G-CSF</arm_group_label>
    <arm_group_label>Etoposide + G-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>375 mg/m2, IV, Once per week for 3 weeks.</description>
    <arm_group_label>Rituxan + Etoposide + G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Patients with B-cell malignancies who are appropriate candidates for high-dose
             chemotherapy and autologous stem cell transplantation and meet 1 of the following
             criteria:

               -  Relapsed or refractory B-cell non-Hodgkin's Lymphoma (NHL)

               -  Patients with B-cell NHL in first remission and who have significant risk for
                  later relapse

               -  Patients with other B-cell malignancies otherwise eligible for autologous stem
                  cell transplantation

        PATIENT CHARACTERISTICS:

          -  Life expectancy at least 2 months

          -  Cardiac ejection fraction ≥ 45%

          -  DLCO ≥ 45%

          -  Creatinine &lt; 2.0 mg/dL

          -  Bilirubin &lt; 2.0 mg/dL

          -  AST &lt; 2 times normal

          -  Platelet count ≥ 50,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Absolute lymphocyte count ≤ 10,000/mm^3

          -  HIV negative

          -  No severe medical or psychiatric illnesses

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  More than 8 weeks since prior rituximab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J. Bolwell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, Dean R, Koo A, Chan J, Sweetenham J, Bolwell B. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant. 2009 Jan;43(2):101-5. doi: 10.1038/bmt.2008.306. Epub 2008 Sep 15.</citation>
    <PMID>18794865</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <last_update_submitted>March 28, 2011</last_update_submitted>
  <last_update_submitted_qc>March 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Brian Bolwell, MD</name_title>
    <organization>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

